Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $11.2 million.

  • Insight Molecular Diagnostics' Operating Expenses fell 1753.04% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year increase of 4608.79%. This contributed to the annual value of $61.8 million for FY2024, which is 14181.38% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Operating Expenses stood at $11.2 million for Q3 2025, which was down 1753.04% from $10.2 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Operating Expenses ranged from a high of $34.2 million in Q4 2024 and a low of -$5.8 million during Q1 2023
  • Its 5-year average for Operating Expenses is $10.3 million, with a median of $10.2 million in 2025.
  • Data for Insight Molecular Diagnostics' Operating Expenses shows a peak YoY increase of 41695.84% (in 2023) and a maximum YoY decrease of 16237.98% (in 2023) over the last 5 years.
  • Over the past 5 years, Insight Molecular Diagnostics' Operating Expenses (Quarter) stood at $17.8 million in 2021, then tumbled by 34.69% to $11.6 million in 2022, then skyrocketed by 38.22% to $16.1 million in 2023, then skyrocketed by 113.06% to $34.2 million in 2024, then crashed by 67.31% to $11.2 million in 2025.
  • Its Operating Expenses stands at $11.2 million for Q3 2025, versus $10.2 million for Q2 2025 and $8.1 million for Q1 2025.